FDA approves somatropin for short stature, Prader-Willi syndrome in children

The FDA has approved an expanded indication for the growth hormone injection somatropin for the treatment of idiopathic short stature and Prader-Willi syndrome in children, Novo Nordisk announced in a press release.

Somatropin (Norditropin) is also indicated to treat children with low or no GH, children with Noonan syndrome, Turner syndrome or who are born small for gestational age, and adults who do not make enough GH.

In 2015, the FDA approved the Norditropin FlexPro 30-mg prefilled pen as an additional option for patients with GH disorders. Other Norditropin products include the 5-mg, 10-mg and 15-mg prefilled pens.

The FDA has approved an expanded indication for the growth hormone injection somatropin for the treatment of idiopathic short stature and Prader-Willi syndrome in children, Novo Nordisk announced in a press release.

Somatropin (Norditropin) is also indicated to treat children with low or no GH, children with Noonan syndrome, Turner syndrome or who are born small for gestational age, and adults who do not make enough GH.

In 2015, the FDA approved the Norditropin FlexPro 30-mg prefilled pen as an additional option for patients with GH disorders. Other Norditropin products include the 5-mg, 10-mg and 15-mg prefilled pens.